Pfizer secures $1.5bn obesity funding

Pfizer clinches $1.5 billion obesity funding deal

Pfizer has secured a strategic co-funding agreement under which funds managed by Blackstone Life Sciences will provide up to $1.5 billion through 2028 to support development of its obesity program. The financing will help fund clinical development of berobenatide, an investigational, potential first-in-class monthly GLP-1 receptor agonist peptide being studied for chronic weight management and obesity-related conditions.

The agreement is structured so that Blackstone will pay up to a total of $1.5 billion of development costs for berobenatide over the multi-year period. This capital is aimed at supporting a broad and rigorous development program for the drug while allowing Pfizer to maintain financial capacity to invest across its wider pipeline.

Key terms of the Blackstone–Pfizer arrangement

In exchange for the development funding, Blackstone will be eligible to receive milestone-based payments. These potential payments are contingent on U.S. regulatory approval of monthly dosing of injectable berobenatide monotherapy for chronic weight management and on achievement of specified commercial sales milestones.

Any milestone payments, if earned, are expected to be made to Blackstone over a multi-year period. Under the terms of the funding agreement, Blackstone does not obtain any rights or ownership in berobenatide, while Pfizer retains full operational control and decision-making authority over the program.

Funds managed by Blackstone’s perpetual private equity strategy will invest alongside funds managed by Blackstone Life Sciences in the transaction. Blackstone described the structure as a capital solution designed to advance the development of important medicines and technologies at scale.

Berobenatide and Pfizer’s obesity pipeline plans

Berobenatide, also known as PF’3944, is being developed as a potential first-in-class monthly GLP-1 receptor agonist peptide. It is being studied for chronic weight management and for obesity-related comorbidities, including knee osteoarthritis and obstructive sleep apnea.

Pfizer plans to advance more than 20 trials for obesity and related comorbidities in 2026. This portfolio includes 10 ongoing and planned Phase 3 trials for berobenatide, reflecting an extensive development strategy that encompasses both monotherapy and combination approaches.

The company is evaluating berobenatide both on its own and in combination with various Nutrient-Stimulated Hormone peptides, including amylin analogs. The development program is supported by a growing body of evidence that underpins the decision to move forward with an expansive clinical plan.

Strategic and financial objectives for the partnership

Pfizer describes the funding agreement as part of a disciplined approach that pairs internal research investment with targeted capital from external partners. The company indicates that this structure is intended to advance its comprehensive obesity program while preserving flexibility to invest in other therapeutic areas.

Blackstone Life Sciences positions the collaboration as an example of its role in providing large-scale capital solutions in the life sciences sector. By co-funding berobenatide’s development, Blackstone aims to support the expansion of Pfizer’s cardiometabolic pipeline, with berobenatide as a central asset.